世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

非侵襲的出生前検査の市場規模、シェア&動向分析レポート:妊娠期間別、妊娠リスク別、方法別、技術別、製品別、用途別、最終用途別、地域別、セグメント別予測、2022年~2030年


Non Invasive Prenatal Testing Market Size, Share & Trends Analysis Report By Gestation Period, By Pregnancy Risk, By Method, By Technology, By Product, By Application, By End-use, By Region, And Segment Forecasts, 2022 - 2030

非侵襲的出生前検査市場の成長とトレンド Grand View Research, Inc.の新しいレポートによると、世界の非侵襲的出生前検査の市場規模は2030年までに77億1000万米ドルに達し、2022年から2030年までCAGR9.61%で... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2022年8月24日 US$5,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
100 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

非侵襲的出生前検査市場の成長とトレンド

Grand View Research, Inc.の新しいレポートによると、世界の非侵襲的出生前検査の市場規模は2030年までに77億1000万米ドルに達し、2022年から2030年までCAGR9.61%で拡大すると予測されています。染色体異常の発生率の増加が、市場の成長を加速させると予想されます。中でも、年間出生数が1465万人近くに上り、高リスクの妊娠が増加している中国では、非侵襲的な出生前スクリーニングに大きな機会があると考えられています。

また、インドでは遺伝性疾患の負担が大きくなっています。様々な研究により、同国では新生児166人に1人の頻度で染色体異常が見つかっており、21トリソミー(ダウン症)は出生800人に1人と高い発生率を示し、毎年3万2千人のダウン症の新生児が誕生していることが報告されています。NIPTを用いた正確かつ早期のスクリーニングにより、赤ちゃんの遺伝的問題を知ることは、家族にとって有益なことです。したがって、この高い発生率は出生前検査の需要を押し上げると予想されます。

COVID-19によるロックダウンを受けて、NIPTは、絨毛膜絨毛サンプリングや羊水穿刺などの侵襲的な処置に比べ、感染リスクを最小限に抑えながら高精度のスクリーニングを実現するため、注目を集めました。さらに、NIPTの処方に対する需要が高まりましたが、ほとんどの国ではインフラが整っていないことや遠隔医療施設の採用により、対象となる人は限られていました。

非侵襲的出生前検査に関する保険償還のシナリオは非常に多様である。しかし、政府からの支援と有利な保険政策が市場の成長を後押ししています。例えば、オランダでは、出生前検査の費用は第2トリメスターで完全に払い戻され、これらのテストの採用が増加しました。インドや中国などの新興国におけるバイオおよび製薬業界を奨励する政府のイニシアティブの増加は、非侵襲的な出生前検査ソリューションおよびサービスの需要を高めると予想されます。

市場の主要企業は、製品ポートフォリオを強化し、顧客に革新的な製品を提供するために、新製品開発に注力しています。2020年3月、アジレント・テクノロジーは、細胞遺伝学研究所による出生前および出生後の研究をサポートする3つの新しいマイクロアレイを発売しました。サイトウ・マイクロアレイのプローブは、体質DNAサンプルにおける神経精神疾患、発達遅延、知的障害、先天異常などに関連するコピー数変異やコピーニュートラルヘテロ接合性消失の高分解能検出を実現します。

非侵襲性出生前検査市場レポートハイライト

- 妊娠期間別では、妊娠第2期に実施される非侵襲的出生前処置の数が最も多いことから、2021年には13-24週が市場を支配した

- 妊娠リスクの低いセグメントは、予測期間中に大きな成長を遂げると予想されます。平均的なリスクの妊娠に対する予算割り当てなど、政府からのサポートがセグメントの成長に寄与した

- 製品別では、母体血漿検査における無細胞DNAのセグメントが2021年に最大の収益シェアを占めました。無細胞DNAは、様々な遺伝子分析を通じて、出生前ケアにおける遺伝性疾患のリスク予測に活用されるようになってきている

- 予測期間中、アジア太平洋地域が最も高いCAGRを示すと予想されます。妊産婦年齢の上昇と医療インフラの整備が市場成長を強化する可能性が高い

- 研究開発投資の多さ、高度な医療施設の存在、全ゲノムシーケンスの発達により、2021年には北米が市場を支配した



ページTOPに戻る


目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Non-Invasive Prenatal Testing Market Variables, Trends, and Scope
3.1 Penetration and Growth Prospect Mapping for Gestation Period
3.1.1 Consumer Behavior Analysis
3.2 Regulatory Framework
3.3 Market Driver Analysis
3.3.1 Increasing Average Maternal Age And Rising Incidence Of Chromosomal Syndromes
3.3.2 High Demand For Early And Noninvasive Fetal Testing Procedure
3.3.3 Improvements In The Reimbursement Scenario
3.3.4 Rising Collaborations And Licensing Agreements
3.4 Market Restraint Analysis
3.4.1 Ethical Concerns With Respect To Reproductive Genetics
3.4.2 Reliability Of Test Results
3.4.3 Pricing Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
3.7 COVID-19 Impact Analysis
Chapter 4 Non-Invasive Prenatal Testing Market - Segment Analysis, by Gestation Period, 2018 - 2030 (USD Million)
4.1 Non-Invasive Prenatal Testing Market: Gestation Period Movement Analysis
4.2 0-12 Weeks
4.2.1 0-12 Weeks Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.3 13-24 Weeks
4.3.1 13-24 Weeks Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4 25-36 Weeks
4.4.1 25-36 Weeks Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Non-Invasive Prenatal Testing Market - Segment Analysis, by Pregnancy Risk, 2018 - 2030 (USD Million)
5.1 Non-Invasive Prenatal Testing Market: Pregnancy Risk Movement Analysis
5.2 High & Average Risk Pregnancy Testing
5.2.1 High & Average Risk Pregnancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.3 Low-Risk Pregnancy Testing
5.3.1 Low-Risk Pregnancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Non-Invasive Prenatal Testing Market - Segment Analysis, by Method, 2018 - 2030 (USD Million)
6.1 Non-Invasive Prenatal Testing Market: Method Movement Analysis
6.2 Ultrasound Detection
6.2.1 Ultrasound Detection Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.3 Biochemical Screening Tests
6.3.1 Biochemical Screening Tests Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.4 Cell-Free Dna In Maternal Plasma Tests
6.4.1 Cell-Free Dna In Maternal Plasma Tests Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Non-Invasive Prenatal Testing Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)
7.1 Non-Invasive Prenatal Testing Market: Technology Movement Analysis
7.2 Next-Generation Sequencing
7.2.1 Next-Generation Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3 Array Technology
7.3.1 Array Technology Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4 Polymerase Chain Reaction (Pcr)
7.4.1 Polymerase Chain Reaction (Pcr) Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5 Other Technologies
7.5.1 Other Technologies Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Non-Invasive Prenatal Testing Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
8.1 Non-Invasive Prenatal Testing Market: Product Movement Analysis
8.2 Consumables and Reagents
8.2.1 Consumables And Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3 Instruments
8.3.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 9 Non-Invasive Prenatal Testing Market - Segment Analysis, by End-Use, 2018 - 2030 (USD Million)
9.1 Non-Invasive Prenatal Testing Market: End-use Movement Analysis
9.2 Hospitals
9.2.1 Hospitals Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.3 Diagnostic Laboratories
9.3.1 Diagnostic Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 10 Non-Invasive Prenatal Testing Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
10.1 Non-Invasive Prenatal Testing Market: Application Movement Analysis
10.2 Trisomy
10.2.1 Trisomy Market Estimates And Forecast, 2018 - 2030 (USD Million)
10.3 Microdeletion Syndrome
10.3.1 Microdeletion Syndrome Market Estimates And Forecast, 2018 - 2030 (USD Million)
10.4 Other Applications
10.4.1 Other Applications Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 11 Non-Invasive Prenatal Testing Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)
11.1 Non-Invasive Prenatal Testing Market: Regional Movement Analysis
11.2 North America
11.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.2.2 U.S.
11.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.2.3 Canada
11.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3 Europe
11.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.2 Germany
11.3.2.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.3 U.K.
11.3.3.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.4 France
11.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.5 Italy
11.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.6 Spain
11.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4 Asia Pacific
11.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.2 Japan
11.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.3 China
11.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.4 India
11.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.5 Singapore
11.4.5.1 Singapore Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.6 Australia
11.4.6.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.5 Latin America
11.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.5.2 Brazil
11.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.5.3 Mexico
11.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.6 MEA
11.6.1 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.6.2 South Africa
11.6.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
11.6.3 Saudi Arabia
11.6.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 12 Non-Invasive Prenatal Testing Market - Competitive Analysis
12.1 Recent Developments & Impact Analysis, by Key Market Participants
12.1.1 Ansoff Matrix
12.2 Company Categorization
12.2.1 Innovators
12.2.2 Market Leaders
12.2.3 Key Company Market Share Analysis, 2021
12.3 Vendor Landscape
12.3.1 List Of Key Distributors And Channel Partners
12.3.2 Key Customers
12.3.3 List Of Key Emerging Companies
12.4 Synergy Analysis: Major Deals & Strategic Alliances
12.4.1 New Product Launch
12.4.2 Acquisitions
12.4.3 Expansion
12.4.4 Partnerships
12.5 Company Profiles
12.5.1 NATERA INC.
12.5.1.1 Company overview
12.5.1.2 Financial performance
12.5.1.3 Product benchmarking
12.5.1.4 Strategic initiatives
12.5.2 CENTOGENE N.V.
12.5.2.1 Company overview
12.5.2.2 Financial performance
12.5.2.3 Product benchmarking
12.5.2.4 Strategic initiatives
12.5.3 ILLUMINA INC (VERINATA HEALTH INC.)
12.5.3.1 Company overview
12.5.3.2 Financial performance
12.5.3.3 Product benchmarking
12.5.3.4 Strategic initiatives
12.5.4 EUROFINS LIFECODEXX GMBH
12.5.4.1 Company overview
12.5.4.2 LifeCodexx AG
12.5.4.3 Financial performance
12.5.4.4 Product benchmarking
12.5.4.5 Strategic initiatives
12.5.5 MEDGENOME
12.5.5.1 Company overview
12.5.5.2 Product benchmarking
12.5.5.3 Strategic initiatives
12.5.6 ARIOSA DIAGNOSTICS (F. HOFFMANN-LA ROCHE LTD.)
12.5.6.1 Company overview
12.5.6.2 Financial performance
12.5.6.3 Product benchmarking
12.5.6.4 Strategic initiatives
12.5.7 MYRIAD WOMEN'S HEALTH, INC. (COUNSYL, INC.)
12.5.7.1 Company overview
12.5.7.2 Financial performance
12.5.7.3 Product benchmarking
12.5.7.4 Strategic initiatives
12.5.8 PROGENITY, INC.
12.5.8.1 Company overview
12.5.8.2 Product benchmarking
12.5.8.3 Strategic initiatives
12.5.9 QIAGEN
12.5.9.1 Company overview
12.5.9.2 Financial performance
12.5.9.3 Product benchmarking
12.5.9.4 Strategic initiatives
12.5.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
12.5.10.1 Company overview
12.5.10.2 Sequenom
12.5.10.3 Integrated Genomics, Inc.
12.5.10.4 Financial performance
12.5.10.5 Product benchmarking
12.5.10.6 Strategic initiatives
12.5.11 QUEST DIAGNOSTICS INCORPORATED
12.5.11.1 Company overview
12.5.11.2 Financial performance
12.5.11.3 Product benchmarking
12.5.11.4 Strategic initiatives

 

ページTOPに戻る


 

Summary

Non Invasive Prenatal Testing Market Growth & Trends

The global non invasive prenatal testing market size is expected to reach USD 7.71 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.61% from 2022 to 2030. Increasing incidence of chromosomal abnormalities is expected to accelerate market growth. Of all the countries, there is a substantial opportunity in China for non invasive prenatal screening, with nearly 14.65 million annual births and increasing number of high-risk pregnancies.

In addition, India has a heavy burden of genetic diseases. Various studies suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth of 32,000 newborns with Down syndrome every year. Families can benefit from accurate and early screening using NIPT to know about their baby's genetic issue. Thus, this high incidence rate is anticipated to boost the demand for prenatal tests.

With lockdowns due to COVID-19, NIPT gained attention because it delivers high accuracy screening with minimum risk of infection compared to invasive procedures like chorionic villus sampling and amniocentesis, both of which may necessitate hospitalization and put patients and medical professionals at risk of contracting COVID-19 infection. Moreover, there was increased demand for prescription of NIPTs; however, it was limited to a smaller number of eligible people due to the lack of infrastructure and adoption of telemedicine facilities in most countries.

The reimbursement scenario pertaining to non invasive prenatal testing is highly variable. However, the support from the government and favorable insurance policies boost market growth. For instance, in the Netherlands, prenatal testing expenses are fully reimbursed in the second trimester, leading to increased adoption of these tests. Increase in government initiatives to encourage the bio- and pharmaceutical industry in emerging economies such as India and China is anticipated to boost the demand for noninvasive prenatal testing solutions and services.

Key players in the market are focusing on new product development to strengthen their product portfolios and offer innovative products to customers. In March 2020, Agilent Technologies launched three new microarrays to support prenatal and postnatal research by cytogenetic laboratories. The probes on the cyto microarrays offer high-resolution detection of copy number variation and copy-neutral loss of heterozygosity related to neuropsychiatric disorders, developmental delay, intellectual disability, and congenital anomalies in constitutional DNA samples.

Non Invasive Prenatal Testing Market Report Highlights

• By gestation period, 13-24 weeks dominated the market in 2021 owing to the maximum number of non-invasive prenatal procedures carried out in the second trimester of the pregnancy

• The low-risk pregnancy risk segment is expected to witness significant growth over the forecast period. Support from the government such as budget assignment for average-risk pregnancies contributed to the segment growth

• Based on product, the cell-free DNA in maternal plasma tests segment accounted for the largest revenue share in 2021. Cell-free DNA is increasingly being utilized in predicting the risk of genetic disorders in prenatal care via various genetic analyses

• Asia Pacific is expected to exhibit the highest CAGR over the forecast period. Rising maternal age and improving healthcare infrastructure are likely to strengthen the market growth

• North America dominated the market in 2021 due to high R&D investments, the presence of advanced healthcare facilities, and the development of whole genome sequencing



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Non-Invasive Prenatal Testing Market Variables, Trends, and Scope
3.1 Penetration and Growth Prospect Mapping for Gestation Period
3.1.1 Consumer Behavior Analysis
3.2 Regulatory Framework
3.3 Market Driver Analysis
3.3.1 Increasing Average Maternal Age And Rising Incidence Of Chromosomal Syndromes
3.3.2 High Demand For Early And Noninvasive Fetal Testing Procedure
3.3.3 Improvements In The Reimbursement Scenario
3.3.4 Rising Collaborations And Licensing Agreements
3.4 Market Restraint Analysis
3.4.1 Ethical Concerns With Respect To Reproductive Genetics
3.4.2 Reliability Of Test Results
3.4.3 Pricing Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
3.7 COVID-19 Impact Analysis
Chapter 4 Non-Invasive Prenatal Testing Market - Segment Analysis, by Gestation Period, 2018 - 2030 (USD Million)
4.1 Non-Invasive Prenatal Testing Market: Gestation Period Movement Analysis
4.2 0-12 Weeks
4.2.1 0-12 Weeks Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.3 13-24 Weeks
4.3.1 13-24 Weeks Market Estimates And Forecast, 2018 - 2030 (USD Million)
4.4 25-36 Weeks
4.4.1 25-36 Weeks Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 5 Non-Invasive Prenatal Testing Market - Segment Analysis, by Pregnancy Risk, 2018 - 2030 (USD Million)
5.1 Non-Invasive Prenatal Testing Market: Pregnancy Risk Movement Analysis
5.2 High & Average Risk Pregnancy Testing
5.2.1 High & Average Risk Pregnancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
5.3 Low-Risk Pregnancy Testing
5.3.1 Low-Risk Pregnancy Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 6 Non-Invasive Prenatal Testing Market - Segment Analysis, by Method, 2018 - 2030 (USD Million)
6.1 Non-Invasive Prenatal Testing Market: Method Movement Analysis
6.2 Ultrasound Detection
6.2.1 Ultrasound Detection Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.3 Biochemical Screening Tests
6.3.1 Biochemical Screening Tests Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.4 Cell-Free Dna In Maternal Plasma Tests
6.4.1 Cell-Free Dna In Maternal Plasma Tests Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 7 Non-Invasive Prenatal Testing Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)
7.1 Non-Invasive Prenatal Testing Market: Technology Movement Analysis
7.2 Next-Generation Sequencing
7.2.1 Next-Generation Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.3 Array Technology
7.3.1 Array Technology Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.4 Polymerase Chain Reaction (Pcr)
7.4.1 Polymerase Chain Reaction (Pcr) Market Estimates And Forecast, 2018 - 2030 (USD Million)
7.5 Other Technologies
7.5.1 Other Technologies Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 8 Non-Invasive Prenatal Testing Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)
8.1 Non-Invasive Prenatal Testing Market: Product Movement Analysis
8.2 Consumables and Reagents
8.2.1 Consumables And Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
8.3 Instruments
8.3.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 9 Non-Invasive Prenatal Testing Market - Segment Analysis, by End-Use, 2018 - 2030 (USD Million)
9.1 Non-Invasive Prenatal Testing Market: End-use Movement Analysis
9.2 Hospitals
9.2.1 Hospitals Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.3 Diagnostic Laboratories
9.3.1 Diagnostic Laboratories Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 10 Non-Invasive Prenatal Testing Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
10.1 Non-Invasive Prenatal Testing Market: Application Movement Analysis
10.2 Trisomy
10.2.1 Trisomy Market Estimates And Forecast, 2018 - 2030 (USD Million)
10.3 Microdeletion Syndrome
10.3.1 Microdeletion Syndrome Market Estimates And Forecast, 2018 - 2030 (USD Million)
10.4 Other Applications
10.4.1 Other Applications Market Estimates And Forecast, 2018 - 2030 (USD Million)
Chapter 11 Non-Invasive Prenatal Testing Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)
11.1 Non-Invasive Prenatal Testing Market: Regional Movement Analysis
11.2 North America
11.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.2.2 U.S.
11.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.2.3 Canada
11.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3 Europe
11.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.2 Germany
11.3.2.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.3 U.K.
11.3.3.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.4 France
11.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.5 Italy
11.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.3.6 Spain
11.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4 Asia Pacific
11.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.2 Japan
11.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.3 China
11.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.4 India
11.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.5 Singapore
11.4.5.1 Singapore Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.4.6 Australia
11.4.6.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.5 Latin America
11.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.5.2 Brazil
11.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.5.3 Mexico
11.5.3.1 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.6 MEA
11.6.1 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
11.6.2 South Africa
11.6.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
11.6.3 Saudi Arabia
11.6.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 12 Non-Invasive Prenatal Testing Market - Competitive Analysis
12.1 Recent Developments & Impact Analysis, by Key Market Participants
12.1.1 Ansoff Matrix
12.2 Company Categorization
12.2.1 Innovators
12.2.2 Market Leaders
12.2.3 Key Company Market Share Analysis, 2021
12.3 Vendor Landscape
12.3.1 List Of Key Distributors And Channel Partners
12.3.2 Key Customers
12.3.3 List Of Key Emerging Companies
12.4 Synergy Analysis: Major Deals & Strategic Alliances
12.4.1 New Product Launch
12.4.2 Acquisitions
12.4.3 Expansion
12.4.4 Partnerships
12.5 Company Profiles
12.5.1 NATERA INC.
12.5.1.1 Company overview
12.5.1.2 Financial performance
12.5.1.3 Product benchmarking
12.5.1.4 Strategic initiatives
12.5.2 CENTOGENE N.V.
12.5.2.1 Company overview
12.5.2.2 Financial performance
12.5.2.3 Product benchmarking
12.5.2.4 Strategic initiatives
12.5.3 ILLUMINA INC (VERINATA HEALTH INC.)
12.5.3.1 Company overview
12.5.3.2 Financial performance
12.5.3.3 Product benchmarking
12.5.3.4 Strategic initiatives
12.5.4 EUROFINS LIFECODEXX GMBH
12.5.4.1 Company overview
12.5.4.2 LifeCodexx AG
12.5.4.3 Financial performance
12.5.4.4 Product benchmarking
12.5.4.5 Strategic initiatives
12.5.5 MEDGENOME
12.5.5.1 Company overview
12.5.5.2 Product benchmarking
12.5.5.3 Strategic initiatives
12.5.6 ARIOSA DIAGNOSTICS (F. HOFFMANN-LA ROCHE LTD.)
12.5.6.1 Company overview
12.5.6.2 Financial performance
12.5.6.3 Product benchmarking
12.5.6.4 Strategic initiatives
12.5.7 MYRIAD WOMEN'S HEALTH, INC. (COUNSYL, INC.)
12.5.7.1 Company overview
12.5.7.2 Financial performance
12.5.7.3 Product benchmarking
12.5.7.4 Strategic initiatives
12.5.8 PROGENITY, INC.
12.5.8.1 Company overview
12.5.8.2 Product benchmarking
12.5.8.3 Strategic initiatives
12.5.9 QIAGEN
12.5.9.1 Company overview
12.5.9.2 Financial performance
12.5.9.3 Product benchmarking
12.5.9.4 Strategic initiatives
12.5.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
12.5.10.1 Company overview
12.5.10.2 Sequenom
12.5.10.3 Integrated Genomics, Inc.
12.5.10.4 Financial performance
12.5.10.5 Product benchmarking
12.5.10.6 Strategic initiatives
12.5.11 QUEST DIAGNOSTICS INCORPORATED
12.5.11.1 Company overview
12.5.11.2 Financial performance
12.5.11.3 Product benchmarking
12.5.11.4 Strategic initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

Grand View Research社の分野での最新刊レポート

  • 最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る